NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
8 trialsNCT05116618 2022-09-21
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged
University of Colorado, Denver
Withdrawn
NCT04044378 2020-05-19
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Peking University People's Hospital
Phase 1/2 Withdrawn
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT01210131 2013-08-27
HX4 in SCLC
Maastricht Radiation Oncology
Phase NA Withdrawn
NCT01707758 2013-05-16
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
University of Kansas Medical Center
Withdrawn
NCT01340729 2013-04-05
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00172367 2008-09-26
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Withdrawn